You probably checked a delivery status today, because modern life is apparently 40% waiting for tiny trucks on a map. Cancer researchers have their own version of that problem: how do you deliver something powerful to the right address without wrecking the whole neighborhood?
That is the basic idea behind datopotamab deruxtecan, mercifully nicknamed Dato-DXd. It is an antibody-drug conjugate, which means it works a bit like a very picky delivery van. The antibody part looks for a marker called TROP2, which many triple-negative breast cancer cells carry on their surface. Once it docks, the drug payload gets brought inside the cancer cell, where it can do its unpleasant little job.
In this BEGONIA study, researchers paired Dato-DXd with durvalumab, an immunotherapy drug that blocks PD-L1, one of cancer’s favorite “nothing to see here” signs for the immune system. If Dato-DXd is the delivery van with a toxic package, durvalumab is the grandchild who says, “No, Grandma, that suspicious van in the driveway is actually important. Please look at it.”
Triple-Negative, Triple-Annoying
Triple-negative breast cancer, or TNBC, gets its name because the tumor lacks three common treatment targets: estrogen receptors, progesterone receptors, and HER2. That means some of the best-known breast cancer treatments do not have a good handle to grab.
This subtype can grow quickly and spread earlier than some other breast cancers. It is not one disease with one neat trick, either. It is more like a junk drawer: some batteries, one mystery key, three rubber bands, and a receipt from 2017. Scientists keep sorting through it because better sorting means better treatment.
Current first-line treatment for advanced TNBC often depends on whether the tumor expresses PD-L1. In the KEYNOTE-355 trial, adding pembrolizumab to chemotherapy improved overall survival for patients whose tumors had higher PD-L1 expression DOI: 10.1056/NEJMoa2202809. That was a real step forward, but it still left a problem: what about people whose cancers do not fit the neat PD-L1-high box?
The BEGONIA Basket
The new paper reports arms 7 and 8 of the phase Ib/II BEGONIA study, testing Dato-DXd plus durvalumab as first-line treatment for unresectable locally advanced or metastatic TNBC DOI: 10.1016/j.annonc.2026.05.693.
Arm 7 enrolled 62 patients regardless of PD-L1 status. Arm 8 enrolled 33 patients with PD-L1-high tumors. Everyone received Dato-DXd plus durvalumab every three weeks.
The results were eye-catching without needing fireworks or a pharmaceutical narrator with a deep voice. In Arm 7, the confirmed objective response rate was 79.0%. Median duration of response was 17.6 months, median progression-free survival was 14.0 months, and median overall survival had not yet been reached at the data cutoff. In Arm 8, the response rate was 81.8%, though follow-up was shorter, so longer-term results were still too young to drive.
That “regardless of PD-L1 status” part matters. If future randomized trials confirm it, this combination could make the treatment cupboard less bare for patients whose tumors are not waving the usual immunotherapy flag.
Why This Combo Makes Sense
Cancer treatment often works better when you stop asking one drug to do the whole family reunion by itself.
TROP2-targeted ADCs have already changed the TNBC conversation. Sacituzumab govitecan, another TROP2-directed ADC, beat standard chemotherapy in previously treated metastatic TNBC in the ASCENT trial DOI: 10.1056/NEJMoa2028485. Reviews of TROP2-targeted therapy describe TROP2 as broadly expressed across breast cancer subtypes, especially TNBC, making it a tempting target for drug delivery DOI: 10.1186/s40364-024-00633-6.
Dato-DXd brings a different antibody-drug design to the table. Early phase data from TROPION-PanTumor01 showed activity in advanced breast cancer, including TNBC DOI: 10.1200/JCO.23.01909. Pairing it with durvalumab is a bit like using soap and water instead of just water: one may loosen the mess, the other helps wash it away. Biology is never that tidy, of course. Biology hears a tidy metaphor and immediately spills soup on it.
The Fine Print, Because Grandma Reads Labels
This was not a phase III trial. It was open-label, relatively small, and not designed to prove the combination beats current standard treatment. Arm 8 also had shorter follow-up, which means some of the most useful numbers are still ripening on the windowsill.
Safety was described as manageable, with no new safety signals compared with prior studies. Still, ADCs and immunotherapy can both cause meaningful side effects. The goal is not just to hit the tumor harder. It is to help people live longer and better, with fewer days spent feeling like the treatment ran over them with a lawn mower.
The next big question is whether larger randomized trials can reproduce these response rates and show survival benefits. If they can, Dato-DXd plus durvalumab could become part of a more personalized first-line strategy for metastatic TNBC, especially for patients who need options beyond the usual PD-L1-based pathways.
For now, BEGONIA gives us a promising signal: a targeted drug delivery system plus an immune checkpoint blocker may help more patients get meaningful tumor shrinkage. Not a cure-all. Not magic. But in a disease as stubborn as TNBC, even a better shovel for the weeds is worth paying attention to.
References
Schmid P, Wang H-C, Lynce F, et al. Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study. Annals of Oncology. 2026. https://doi.org/10.1016/j.annonc.2026.05.693
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New England Journal of Medicine. 2022;387:217-226. https://doi.org/10.1056/NEJMoa2202809
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. New England Journal of Medicine. 2021;384:1529-1541. https://doi.org/10.1056/NEJMoa2028485
Bardia A, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. Journal of Clinical Oncology. 2024;42:2281-2294. https://doi.org/10.1200/JCO.23.01909
Liang Y, Zhang H, Song X, Yang Q. Trop2-targeted therapy in breast cancer. Biomarker Research. 2024;12:82. https://doi.org/10.1186/s40364-024-00633-6
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.